BNP Paribas Discount Zert SNW 27..../ DE000PC0NTD5 /
5/15/2024 9:40:12 PM | Chg.-1.210 | Bid9:59:49 PM | Ask9:59:49 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
90.270EUR | -1.32% | - Bid Size: - |
- Ask Size: - |
SANOFI SA INHABER ... | - - | 6/27/2024 | Call |
GlobeNewswire
2:00 PM
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients wit...
GlobeNewswire
5/13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
5/13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
5/13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
5/10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
5/8
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/7
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
5/2
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire
4/25
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire
4/23
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia